Dobrecky-Mery Idit

TECHNION – RUTH & BRUCE RAPPAPORT FACULTY OF MEDICINE

TECHNION – RUTH & BRUCE RAPPAPORT FACULTY OF MEDICINE

RESUME

 

1.    PERSONAL DETAILS

 

Full Name: Idit Dobrecky-Mery

Identity No.: 23939200

Date and place of birth: July 18, 1969; Nahariya, Israel

Marital status: married

Phone numbers: 972-7-6564650; 972-50-7334460

Email: iditmery@walla.co.il

 

  1. ACADEMIC DEGREES

 

1996      MD, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

1993      BSc, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

 

  1. ACADEMIC APPOINTMENTS

 

2012 to present    Adjunct lecturer, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

 

  1. PROFESSIONAL EXPERIENCE

 

2019 to present    Director, Cardiology Department, Bnai Zion Medical Center, Haifa, Israel

2012 – 2019        Director, Coronary Care Unit, Bnai Zion Medical Center, Haifa, Israel

2011 – 2012        Attending Physician, Cardiology Department, Bnai Zion Medical Center, Haifa, Israel

2009 to present    Cardiology specialist, Clinical Community Cardiology: Primary and Secondary Prevention Program, Northern Israel communities

2006 – 2009        Fellow, Radiology Department (Cardiac CTA), Lady Davis Carmel Medical Center, Haifa, Israel

2006 to present    Founder and Director, Primary and Secondary Prevention Program, Northern Israel communities, including initiating lectures in the community for primary and secondary prevention

2002 – 2006        Resident, Cardiology, Lady Davis Carmel Medical Center, Haifa, Israel

1999 – 2001        Resident, Internal Medicine, Lady Davis Carmel Medical Center, Haifa, Israel

1997 – 1998        Internship,   Lady Davis Carmel Medical Center, Haifa, Israel

 

  1. RESEARCH INTERESTS

 

  1. Coronary Artery Disease (CAD): Primary and secondary prevention; Intensification of community clinics; CAD risk factor modification; Diabetes type 2 – pharmacotherapy in acute and chronic phases of CVD patients
  2. Cardiac Computed Tomography Angiography (CTA): Classification of different plaques; plaque vulnerability

 

  1. TEACHING EXPERIENCE

 

1998 – 2001        Internal Medicine course, undergraduate students, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

2003 – 2006        Cardiology course, undergraduate students, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

2011 to present    Teaching and tutoring 4th-, 5th– and 6th-year students, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

2015 to present    Continuing education courses in cardiology, cardiologists and family practitioners, Technion – Israel Institute of Technology, Haifa, Israel

2015 to present    Continuing education courses in cardiology, 4th-, 5th– and 6th-year students, School of Medicine, Tel Aviv University, Tel Aviv, Israel

 

  1. TECHNION ACTIVITIES

 

  1. FACULTY ACTIVITIES

 

2016 to present    Chair of the committee determining the cardiology curriculum for residents

                

  1. PUBLIC PROFESSIONAL ACTIVITIES

 

2020 – 2021        Member of the Judging Committee for Outstanding Publications, ISH Society

2018 to present    Member of the committee for writing examinations in cardiology for residents (1st and 2nd level exams), Israel Heart Society

2018                    Reviewer of the Guidelines for Diabetes, Pre-Diabetes and Cardiovascular Disease, European Society of Cardiology

2015 to present    Examiner of cardiology residents’ 1st and 2nd level exams, Israel Heart Society

2006 to present    Founder and Director, Primary and Secondary Prevention Program, Northern Israel communities

 

  1. MEMBERSHIP IN PROFESSIONAL SOCIETIES

 

International

2016 to present            European Heart Society

2018 to present            Acute Cardiovascular Care Association (ACCA)

 

National

2000 to present            Israel Medical Association

2008 to present            Israeli Heart Society

 

 

 

  1. AWARDS AND HONORS

 

2001, 2002, 2006, 2012-2020

Outstanding Lecturer, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

2008      Distinction in Cardiology Residency, Lady Davis Carmel Medical Center, Haifa, Israel

2018      ACCA – ESC finalist in “Best Research” Competition, Research Prize in Cardiology

 

  1. GRADUATE STUDENTS

 

MD Theses in Progress

2019      Aviva Calamaro, Retrospective study on lower dose Apixaban, Dabigatran, and Rivaroxaban usage in patients with atrial fibrillation and renal failure. Primary supervisor: Idit Dobrecky-Mery

2019      Karram Shalaata, Effects of GLP-Z analogies on atherosclerosis. Primary supervisor: Idit Dobrecky-Mery

2019      Sabreen Hassanain,   Comparison of real-world treatment ON CV outcomes and safety with Ticagrelol versus Prasugrel in ACS. Primary supervisor: Idit Dobrecky-Mery

2019      Orel Ben Court, Incidence of atrial fibrillation following myocardial infarction and percutaneous coronary intervention. Primary supervisor: Idit Dobrecky-Mery

2020      Kareem Hijazy, Prevalence of heart arrhythmias after treatment  in STEMI patients. Primary supervisor: Idit Dobrecky-Mery

2021      Omer Weil, FFR – 5-year MACE post coronary catheterization. Primary supervisor: Idit Dobrecky-Mery

 

 

 

  1. RESEARCH GRANTS

 

Industrial

2012    Novartis, 500,000 NIS, Galvus trial – DPP4 in the setting of acute coronary syndrome in type 2 diabetes mellitus: efficacy and safety. PI: Idit Dobrecky-Mery

2019    Sanofi Aventis, 870,000 Euro, PCSK9AB trial – lower perioperative cardiac complications in PCSK9 inhibitors-treated cardiac patients undergoing non-cardiac surgery. PI: Idit Dobrecky-Mery

2020   Novo Nordisk, 550,000 NIS, GLP 1 ana during ACS as inflammatory modulator beyond high dose statin. PI: Idit Dobrecky-Mery

 

  1. PUBLICATIONS

 

14.1   Theses

 

14.2   Refereed Papers in Professional Journals

 

Clinical Research

  1. Halon DA, Adawi S, Dobrecky-Mery I, Lewis BS. Importance of increasing age on the presentation and outcome of acute coronary syndromes in elderly patients. J Am Coll Cardiol, 2004; 43: 346-352.
  2. Shiran A, Adawi S, Dobrecky-Mery I, Halon DA, Lewis BS. Echocardiographic predictors of late mortality in elderly patients with acute coronary syndromes. Isr Med Assoc J, 2007; 9: 247-251.
  3. Halon DA, Dobrecky-Mery I, Gaspar T, Azencot M, Yaniv N, Peled N, Lewis BS. Pulse pressure and coronary atherosclerosis in asymptomatic type 2 diabetes mellitus: A 64 channel cardiac computed tomography analysis. Int J Cardiol, 2010; 143: 63-71.
  4. Halon DA, Dobrecky-Mery I, Gaspar T, Azencot M, Yaniv N, Peled N, Lewis BS. Heart rate recovery after exercise and coronary atheroma in asymptomatic individuals with type 2 diabetes mellitus: a study using 64-slice coronary CT angiography. Int J Cardiol, 2010; 145: 102-103.
  5. Khashper A, Gaspar T, Azencot M, Dobrecky-Mery I, Peled N, Lewis BS, Halon DA. Visceral abdominal adipose tissue and coronary atherosclerosis in asymptomatic diabetics. Int J Cardiol, 2013; 162: 184-188.
  6. Zafrir B, Azaiza M, Gaspar T, Dobrecky-Mery I, Azencot M, Lewis BS, Rubinstein R, Halon DA. Low cardiorespiratory fitness and coronary artery calcification: Complementary cardiovascular risk predictors in asymptomatic type 2 diabetics. Atherosclerosis, 2015; 241: 634-640.
  7. Lubovich A, Dobrecky-Mery I, Radzishevski E, Samnia N, Matetzky S, Nagler R, Rosenschein U. Bypassing the emergency room to reduce door-to-balloon time and improve outcomes of ST elevation myocardial infarction patients: analysis of data from 2004-2010 ACSIS registry. J Interv Cardiol, 2015; 28: 141-146.
  8. Zafrir B, Khashper A, Gaspar T, Dobrecky-Mery I, Azencot M, Lewis BS, Rubinstein R, Halon DA. Prognostic impact of abdominal fat distribution and cardiorespiratory fitness in asymptomatic type 2 diabetics. Eur J Prev Cardiol, 2015; 22: 1146-1153.
  9. Schiff E, Dobrecky-Mery I, Attias S, Ben-Arye E, Kreindler G, Avneri O, Ben Ezra A, Arnon Z, Grinberg I, Rosenschein U. [Integration of complementary medicine in hospital departments: implementation model and research outline in the Cardiology Department]. Harefuah, 2015 Jan; 154: 35-8 (in Hebrew).
  10. Zafrir B, Azencot M, Dobrecky-Mery I, Lewis BS, Flugelman MY, Halon DA. Resting heart rate and measures of effort-related cardiac autonomic dysfunction predict cardiovascular events in asymptomatic type 2 diabetes. Eur J Prev Cardiol, 2016; 23: 1298-1306.
  11. Dobrecky-Mery I, Somer A. Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients. Coronary Artery Dis, 2021; 32: 4-9. IF=1.335 CARDIAC & CARDIOVASCULAR SYSTEMS – Q4.

 

Case Reports

  1. Levy I, Ginsberg S, Tadmor T, Schliamser L, Rimar D, Kessel A, Paz A, Croitoru M, Solopov A, Dobrecky-Mery I, Weller B, Jiries N. An almost fatal case of the hypereosinophilic syndrome: a dilemma between vasculitis or clonal disorder. Journal of Clinical and Medical Case Reports 2019 Dec; IF and Q: N/A

 

Review Papers

  1. Saghiv SM, Goldhammer E, Dobrecky-Mery I. The effects of exercise training on circulating soluble-klotho i in healthy subjects and in coronary artery disease patients. World J of Cardiology 2019;
  2. Tomer O, Leibowitz D, Einhorn-Cohen M, Shlomo N, Goldenberg I, Dobrecky-Mery I, Blatt A, Meisel S, Alcalai A. The impact of length of hospital stay on prognosis after acute myocardial infarction: an analysis from the ACSIS database. Cardiovascular Quality and Outcomes
  3. Dobrecky-Mery I, Somer A, Radizishevsky E, Rivlin E, Mahmod H, Gassan Z, Rosenschein U. Renal safety in diabetic acute coronary syndrome patients treated with Vildagliptin. Int J Cardiology IF=3.229, CARDIAC & CARDIOVASCULAR SYSTEMS Q2
  4. Dobrecky-Mery I, Somer A. Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients. Coronary Artery Disease 2020 April 16. IF=1.335, CARDIAC &CARDIOVASCULAR SYSTEMS Q4, PERIPHERAL VASCULAR DISEASE Q n/a
  5. Redaa A, Almahmeedb W, Dobrecky-Mery I, Huang PH, Juarez-Herrera U, Ranjith N, Sayre T, Urina-Triana M. A narrative review and expert panel recommendations on dyslipidemia management after acute coronary syndrome in countries outside Western Europe and North America. Role: Co-Investigator. Adv Ther, 2020; 37:1754-1777. IF=3.871, MEDICINE, RESEARCH & EXPERIMENTAL Q2, PHARMACOLOGY & PHARMACY Q1.

 

  1. CONFERENCES

 

15.1   Plenary, Keynote or Invited Talks

International

  1. Dobrecky-Mery I. PCSK9 inhibition insights from clinical trials to daily practice. Russian Lipid Academy Meeting, Moscow, Russia, April 2019 (invited talk).

 

 

 

15.2   Contributed Talks and Posters

 

Oral Presentations

International

  1. Dobrecky-Mery I, Gaspar T, Azencot M, Peled N, Nisan Y, Davidov V, Margolis T, Haddad E, Lewis BS, Halon DA. Framingham and UKPDS risk scores predict extent and severity of coronary disease as determined by 64-slice coronary CT angiography in asymptomatic patients with type 2 diabetes mellitus. Cardiovascular Medicine and Radiology, American College of Cardiology Meeting, Chicago, USA, March 2009.
  2. Dobrecky-Mery I, Halon DA, Gaspar T, Azencot M, Nisan Y, Peled N, Lewis BS. Heart rate recovery after exercise and coronary atheroma in asymptomatic individuals with type 2 diabetes mellitus: a study using 64-slice coronary CT angiography. European Society of Cardiology Meeting, Munich, Germany, September
  3. Dobrecky-Mery I, Rosenschein U. Renal safety among ACS patients under treatment with Galvus (Vidagliptin). American Diabetes Association Meeting, Boston, USA, June 2015.
  4. Dobrecky-Mery I, Somer A, Gassan Z, Ghanayim M, Rosenschein U. Blood glucose control in ACS patients treated with Vildagliptin vs standard treatment. European Society of Cardiology Meeting, London UK, September
  5. Dobrecky-Mery I. Hypoglycemic events during hospitalization in diabetic acute coronary syndrome patients treated with vildagliptin vs. guidelines-based medical therapy. ACCA, Milan, Italy, March 2018.
  6. Dobrecky-Mery I. PCSK9 inhibition insights from clinical trials to daily practice. Russian Lipid Academy Conference, Moscow, Russia, April 2019.
  7. Dobrecky-Mery I. Lecture on the American Diabetes Association. American Diabetes Association 80th Scientific Sessions (virtual conference), Virginia, USA, June 2020.

 

National

  1. Dobrecky-Mery I, Weber G. Non-perfringens clostridial infection. Israel Society of Internal Medicine, city, November 1999.
  2. Dobrecky-Mery I, Gaspar T, Azencot M, Peled N, Nisan Y, Davidov V, Margolis T, Haddad E, Lewis BS, Halon DA. Framingham and UKPDS risk scores predict extent and severity of coronary disease as determined by 64-slice coronary CT angiography in asymptomatic patients with type 2 diabetes mellitus. Israel Heart Society Meeting, Haifa, April 2009.
  3. Gaspar T, Dobrecky-Mery I, Aizencot M, Peled N, Yaniv N, Davidov V, Haddad E, Radan A, Lewis BS, Halon DA. Can benefit be expected from further risk factor modification in treated diabetics with pre-clinical coronary artery disease? A 64-Slice coronary CT angiography study. Israel Heart Society Meeting, Haifa, April 2009.
  4. Gaspar T. Dobrecky-Mery I, Aizencot M, Peled N, Nisan Y, Davidov V, Haddad Elie, Radan A, Lewis BS, Halon DA. Modification in treated diabetics with pre-clinical coronary artery disease? A 64-slice coronary CT angiography study. Israel Heart Society Meeting, Tel Aviv, April 2009.
  5. Halon D, Gaspar T, Dobrecky–Mery I, Azencot M, Nisan Y, Peled N, Lewis BS. Statin therapy and coronary plaque characteristics on 64-slice cardiac CT in asymptomatic type 2 diabetic patients. Israel Heart Society Meeting, Haifa, April 2009.
  6. Dobrecky-Mery I, Gaspar T, Azencot M, Peled N, Yaniv N, Rozenblum L, Vishnyak P, Facher Eldeen S, Lewis BS, Halon DA. Heart rate recovery immediately after exercise is a predictor of pre-clinical coronary atheroma in asymptomatic type 2 diabetes. Israel Heart Society Meeting, Tel Aviv, April 2009.
  7. Hassan A, Storch S, Sharif D, Dobrecky-Mery I, Rosenschein U. Catheter-based renal sympathetic denervation (RDN) for resistant hypertension: initial experience. Israel Heart Society Meeting, Tel Aviv, April 2012.
  8. Dobrecky-Mery I, Hamud M, Radizshevsky E Rochfleish S, Rosenschein U. Differences in the need for revascularization in TAO study based on the new HsTnT essay. Israel Heart Society Meeting, Jerusalem, June 2013.
  9. Dobrecky-Mery I, Matetzky S, Lubetsky A. Stroke prevention in atrial fibrillation. Israel Heart Society Meeting, Tel Aviv, April 2017.
  10. Dobrecky-Mery I. Perioperative acute cardiac care. 10th International Conference on Acute Cardiac Care, Tel Aviv, June 2017.
  11. Haydar M, Azzam E, Samniah N, Sharif-Rasslan A, Sharif D, Dobrecky-Mery I. Tricuspid valve regurgitation after right ventricular lead implantation. 66th Annual Conference of the Israel Heart Society, Tel Aviv, April 2019.
  12. Dobrecky-Mery I. Innovation in diabetic pharmacotherapy to improve cardiovascular outcomes. 66th Annual Conference of the Israel Heart Society, Tel Aviv, April 2019.
  13. Dobrecky-Mery I, Abu Mouch I. Scleroderma crisis. 66th Annual Conference of the Israel Heart Society, Tel Aviv, April 2019.
  14. Dobrecky-Mery I. Significance of cardiovascular aspects in the treatment and monitoring of patients with hepatitis C red bulbs. Updates in Hepatology, Herzeliya September 2019.

 

Poster Presentations

International

  1. Dobrecky-Mery I. Re-hospitalization in type 2 diabetes mellitus. American Diabetes Association Meeting, New Orleans, USA, June 2016.
  2. Dobrecky-Mery I. ACS patients treated with Vildagliptin vs. standard treatment. American Diabetes Association Meeting, New Orleans, USA, June 2016.
  3. Sharif D, Haydar M, Azzam E, Sharif-Rasslan A, Dobrecky-Mery I. Bicuspid aortic valve: Differences between populations. EuroEcho, Vienna, Austria, September 2019.
  4. Haydar M, Azzam E, Samniah N, Sharif-Rasslan R, Sharif D, Dobrecky-Mery I, Dynamics of tricuspid regurgitation after right ventricular lead implantation. EuroEcho, Vienna, Austria, September 2019.

 

National

  1. Bradichansky L, Goldhammer E, Radzishevsky E, Samnia N, Dobrecky-Mery I, Rosenschein U. Different patterns of cardiac rehabilitation program results among surgical aortic valve replacement (AVR) and transaortic valve implantation (Tavi) patients. 66th Annual Conference of the Israel Heart Society, Tel Aviv, April 2019.
  2. Azzam E, Sharif D, Odeh M, Dobrecky-Mery I. Bicuspid aortic valve: differences between populations in Israel. 66th Annual Conference of the Israel Heart Society, Tel Aviv, April 2019.

 

15.3   Participation in Organizing Conferences

  1. Woman’s Heart conference, annual conference with lecturers from Israel and abroad, Upper Galilee, July 2017-2018 (co-organizer and co-chair).
  2. Updates in Cardiology, semi-annual conferences for community physicians, Haifa, Israel, March and September 2017-2019 (co-organizer).
  3. Thrombosis and Cardiovascular Medicine – ICI meeting. Tel Aviv, Israel, December 10, 2019 (co-chair).
  4. Therapies, How Can We Best Reduce CV Risk in Patients with Diabetes Transforming Diabetes Management in Cardiology: Impact of Novel – ICI Meeting, Tel Aviv, Israel, December 10, 2019 (co-chair).
  5. IDSS-16th International Dead Sea Symposium on Innovations and Cardiac Arrythmias and Heart Failure, Tel Aviv, Israel, February 24-26, 2020 (chair).
  6. Covid-19 and Cardio-Oncology .Oncology/Hematology/Cardiology. Israeli Cardio-Oncology Society Virtual Meeting. Towards A Comprehensive Cardiac-Cancer Care, Israel, January 13-14, 2021 (chair).
  7. Updates in Cardiology, Israel, February 2021 (chair).

 

  1. SIGNIFICANT PROFESSIONAL PROJECTS/ACTIVITIES

 

Site participation in the following multicenter clinical trials

2005      CLARITY-TIMI 28: Addition of Clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. Role: Co-Investigator.

2007      EXTRACT-TIMI 25: Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. Role: Co-Investigator.

2007 TRITON TIMI-38: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction: double-blind, randomized controlled trial. Role: Co-Investigator.

2012 EVOLVE Trial™: Evaluation of Cinacalcet HCl therapy to lower cardio-vascular events. Role: Co-Investigator.

2013 TAO. Effect of Otamixaban versus unfractionated Heparin + Eptifibatide in patients with unstable angina/non-ST elevation myocardial infarction undergoing early invasive strategy. Role: Co-Investigator.

2014 PRESERVATION: a placebo-controlled, multicenter, randomized, double-blind trial to evaluate the safety and effectiveness of IK-5001 for the prevention of remodeling of the ventricle and congestive heart failure after acute myocardial infarction. Role: Co-Investigator.

2015 RIVER PCI: Ranolazine for incomplete vessel revascularization post-percutaneous coronary intervention (PCI). Role: Co-Investigator.

2015 PARAGON: a multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to Valsartan, on morbidity and mortality in hearty failure patients (NYHA Class II-IV) with preserved ejection fraction patients. Role: Co-Investigator.

2016 DAL 301 TRIAL: a phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial. Role: Co-Investigator.

2018 ODYSSEY OUTCOME: open label treatment with Praluent for patients who participated in EFC11570 STUDY. Duration: 3 years. Role: Co-Investigator.

2018 SCORED TRIAL: a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the effects of Sotagliflozin on cardiovascular and renal events in patients with Type 2 diabetes, cardiovascular risk factors and moderately impaired renal function. Role: Co-Investigator.

2020 FINE ARTS HF: study to evaluate the efficacy (effect on disease) and safety of Finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40%

2020 SURPASS-I TRIAL: study of Tirzepatide (LY3298176) in participants with Type 2 diabetes not controlled with diet and exercise alone

2020 AEGIS-II TRIAL: study to investigate CSL112 in Subjects with acute coronary syndrome (AEGIS-II)

  • Location: Israel
Back to Faculty Back to ICI Program

Tel Aviv, Israel

Tel: +972-55-885-2803
Email: secretariat@icimeeting.com
Poster Submission Startup competition Register now